Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial.
Xu L, Chen J, Liu C, Song X, Zhang Y, Zhao H, Yan S, Jia W, Wu Z, Guo Y, Yang J, Gong W, Ma Y, Yang X, Gao Z, Zhang N, Zheng X, Li M, Su D, Chen M.
Xu L, et al. Among authors: gao z.
BMC Med. 2024 Apr 23;22(1):172. doi: 10.1186/s12916-024-03356-5.
BMC Med. 2024.
PMID: 38650037
Free PMC article.
Clinical Trial.